What to look for in novel CLL therapies
Current research into JAK inhibitors - specifially ruxolitinib, pacritinib, and momelotinib
Haifa Kathrin Al-Ali
The potential for patient-level data in the NHS
Infrastructure for AML treatment in Spain
Why are new molecules typically combined with standard chemotherapy?